Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia
Waldenstrom macroglobulinemia (WM) is a type of incurable, indolent B-cell lymphoma that is prone to relapse. Over time, treatment strategies have progressed from cytotoxic drugs to rituximab (R)- or bortezomib (V)-based regimens, and have now entered into an era of Bruton tyrosine kinase inhibitor...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wolters Kluwer Health
2024-01-01
|
| Colección: | Blood Science |
| Acceso en línea: | http://journals.lww.com/10.1097/BS9.0000000000000179 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|